Posted by Michael Wonder on 07 Dec 2024
PIF Partners granted FDA rare paediatric disease designation for its proprietary small molecule in treating systemic juvenile idiopathic arthritis flares
3 December 2024 - PIF Partners announced today that the US FDA has granted rare paediatric disease designation to its proprietary investigational therapeutic 101-PGC-005 for the treatment of systemic juvenile idiopathic arthritis flares.
101-PGC-005 is a type IA pro-drug of dexamethasone that targets CD206 positive macrophages.
